Optimized sequential therapy < em > vs < /em > 10- and 14-d concomitant therapy for eradicating < em > Helicobacter pylori < /em > : A randomized clinical trial
CONCLUSION: The optimized 14-d sequential therapy is a safe and effective alternative. Its eradication rate is comparable to that of the 14-d concomitant therapy while causing fewer AEs and allowing a gain in terms of cost.PMID:38463026 | PMC:PMC10921140 | DOI:10.3748/wjg.v30.i6.556 (Source: World Journal of Gastroenterology : WJG)
Source: World Journal of Gastroenterology : WJG - March 11, 2024 Category: Gastroenterology Authors: Hassan Seddik Jihane Benass Sanaa Berrag Asmae Sair Reda Berraida Hanae Boutallaka Source Type: research
Optimized sequential therapy < em > vs < /em > 10- and 14-d concomitant therapy for eradicating < em > Helicobacter pylori < /em > : A randomized clinical trial
CONCLUSION: The optimized 14-d sequential therapy is a safe and effective alternative. Its eradication rate is comparable to that of the 14-d concomitant therapy while causing fewer AEs and allowing a gain in terms of cost.PMID:38463026 | PMC:PMC10921140 | DOI:10.3748/wjg.v30.i6.556 (Source: World Journal of Gastroenterology : WJG)
Source: World Journal of Gastroenterology : WJG - March 11, 2024 Category: Gastroenterology Authors: Hassan Seddik Jihane Benass Sanaa Berrag Asmae Sair Reda Berraida Hanae Boutallaka Source Type: research
Optimized sequential therapy < em > vs < /em > 10- and 14-d concomitant therapy for eradicating < em > Helicobacter pylori < /em > : A randomized clinical trial
CONCLUSION: The optimized 14-d sequential therapy is a safe and effective alternative. Its eradication rate is comparable to that of the 14-d concomitant therapy while causing fewer AEs and allowing a gain in terms of cost.PMID:38463026 | PMC:PMC10921140 | DOI:10.3748/wjg.v30.i6.556 (Source: World Journal of Gastroenterology)
Source: World Journal of Gastroenterology - March 11, 2024 Category: Gastroenterology Authors: Hassan Seddik Jihane Benass Sanaa Berrag Asmae Sair Reda Berraida Hanae Boutallaka Source Type: research
Optimized sequential therapy < em > vs < /em > 10- and 14-d concomitant therapy for eradicating < em > Helicobacter pylori < /em > : A randomized clinical trial
CONCLUSION: The optimized 14-d sequential therapy is a safe and effective alternative. Its eradication rate is comparable to that of the 14-d concomitant therapy while causing fewer AEs and allowing a gain in terms of cost.PMID:38463026 | PMC:PMC10921140 | DOI:10.3748/wjg.v30.i6.556 (Source: World Journal of Gastroenterology : WJG)
Source: World Journal of Gastroenterology : WJG - March 11, 2024 Category: Gastroenterology Authors: Hassan Seddik Jihane Benass Sanaa Berrag Asmae Sair Reda Berraida Hanae Boutallaka Source Type: research
Optimized sequential therapy < em > vs < /em > 10- and 14-d concomitant therapy for eradicating < em > Helicobacter pylori < /em > : A randomized clinical trial
CONCLUSION: The optimized 14-d sequential therapy is a safe and effective alternative. Its eradication rate is comparable to that of the 14-d concomitant therapy while causing fewer AEs and allowing a gain in terms of cost.PMID:38463026 | PMC:PMC10921140 | DOI:10.3748/wjg.v30.i6.556 (Source: World Journal of Gastroenterology)
Source: World Journal of Gastroenterology - March 11, 2024 Category: Gastroenterology Authors: Hassan Seddik Jihane Benass Sanaa Berrag Asmae Sair Reda Berraida Hanae Boutallaka Source Type: research
Optimized sequential therapy < em > vs < /em > 10- and 14-d concomitant therapy for eradicating < em > Helicobacter pylori < /em > : A randomized clinical trial
CONCLUSION: The optimized 14-d sequential therapy is a safe and effective alternative. Its eradication rate is comparable to that of the 14-d concomitant therapy while causing fewer AEs and allowing a gain in terms of cost.PMID:38463026 | PMC:PMC10921140 | DOI:10.3748/wjg.v30.i6.556 (Source: World Journal of Gastroenterology : WJG)
Source: World Journal of Gastroenterology : WJG - March 11, 2024 Category: Gastroenterology Authors: Hassan Seddik Jihane Benass Sanaa Berrag Asmae Sair Reda Berraida Hanae Boutallaka Source Type: research
Optimized sequential therapy < em > vs < /em > 10- and 14-d concomitant therapy for eradicating < em > Helicobacter pylori < /em > : A randomized clinical trial
CONCLUSION: The optimized 14-d sequential therapy is a safe and effective alternative. Its eradication rate is comparable to that of the 14-d concomitant therapy while causing fewer AEs and allowing a gain in terms of cost.PMID:38463026 | PMC:PMC10921140 | DOI:10.3748/wjg.v30.i6.556 (Source: World Journal of Gastroenterology)
Source: World Journal of Gastroenterology - March 11, 2024 Category: Gastroenterology Authors: Hassan Seddik Jihane Benass Sanaa Berrag Asmae Sair Reda Berraida Hanae Boutallaka Source Type: research
Optimized sequential therapy < em > vs < /em > 10- and 14-d concomitant therapy for eradicating < em > Helicobacter pylori < /em > : A randomized clinical trial
CONCLUSION: The optimized 14-d sequential therapy is a safe and effective alternative. Its eradication rate is comparable to that of the 14-d concomitant therapy while causing fewer AEs and allowing a gain in terms of cost.PMID:38463026 | PMC:PMC10921140 | DOI:10.3748/wjg.v30.i6.556 (Source: World Journal of Gastroenterology : WJG)
Source: World Journal of Gastroenterology : WJG - March 11, 2024 Category: Gastroenterology Authors: Hassan Seddik Jihane Benass Sanaa Berrag Asmae Sair Reda Berraida Hanae Boutallaka Source Type: research
Optimized sequential therapy < em > vs < /em > 10- and 14-d concomitant therapy for eradicating < em > Helicobacter pylori < /em > : A randomized clinical trial
CONCLUSION: The optimized 14-d sequential therapy is a safe and effective alternative. Its eradication rate is comparable to that of the 14-d concomitant therapy while causing fewer AEs and allowing a gain in terms of cost.PMID:38463026 | PMC:PMC10921140 | DOI:10.3748/wjg.v30.i6.556 (Source: World Journal of Gastroenterology)
Source: World Journal of Gastroenterology - March 11, 2024 Category: Gastroenterology Authors: Hassan Seddik Jihane Benass Sanaa Berrag Asmae Sair Reda Berraida Hanae Boutallaka Source Type: research
Optimized sequential therapy < em > vs < /em > 10- and 14-d concomitant therapy for eradicating < em > Helicobacter pylori < /em > : A randomized clinical trial
CONCLUSION: The optimized 14-d sequential therapy is a safe and effective alternative. Its eradication rate is comparable to that of the 14-d concomitant therapy while causing fewer AEs and allowing a gain in terms of cost.PMID:38463026 | PMC:PMC10921140 | DOI:10.3748/wjg.v30.i6.556 (Source: World Journal of Gastroenterology : WJG)
Source: World Journal of Gastroenterology : WJG - March 11, 2024 Category: Gastroenterology Authors: Hassan Seddik Jihane Benass Sanaa Berrag Asmae Sair Reda Berraida Hanae Boutallaka Source Type: research
Optimized sequential therapy < em > vs < /em > 10- and 14-d concomitant therapy for eradicating < em > Helicobacter pylori < /em > : A randomized clinical trial
CONCLUSION: The optimized 14-d sequential therapy is a safe and effective alternative. Its eradication rate is comparable to that of the 14-d concomitant therapy while causing fewer AEs and allowing a gain in terms of cost.PMID:38463026 | PMC:PMC10921140 | DOI:10.3748/wjg.v30.i6.556 (Source: World Journal of Gastroenterology)
Source: World Journal of Gastroenterology - March 11, 2024 Category: Gastroenterology Authors: Hassan Seddik Jihane Benass Sanaa Berrag Asmae Sair Reda Berraida Hanae Boutallaka Source Type: research
Exploring novel pyrazole-nitroimidazole hybrids: Synthesis and antiprotozoal activity against the human pathogen trichomonas vaginalis
In this study, we synthesized ten pyrazole-nitroimidazoles 1(a-j) and 4-nitro-1-(hydroxyethyl)-1H-imidazole 2, an analog of metronidazole (MTZ), and assessed their trichomonacidal and cytotoxic effects. All compounds 1(a-j) and 2 exhibited IC50 values ≤ 20 μM and ≤ 41 μM, after 24 h and 48 h, respectively. Compounds 1d (IC50 5.3 μM), 1e (IC50 4.8 μM), and 1i (IC50 5.2 μM) exhibited potencies equivalent to MTZ (IC50 4.9 μM), the reference drug, after 24 h. Notably, compound 1i showed high anti-trichomonas activity after 24 h (IC50 5.2 μM) and 48 h (IC50 2.1 μM). Additionally, all compounds demonstrated either no...
Source: Bioorganic and Medicinal Chemistry - March 10, 2024 Category: Chemistry Authors: Rafaela Corr êa Silva Anna De Freitas Bruno Vicente Victor Midlej Maur ício Silva Dos Santos Source Type: research
Exploring novel pyrazole-nitroimidazole hybrids: Synthesis and antiprotozoal activity against the human pathogen trichomonas vaginalis
In this study, we synthesized ten pyrazole-nitroimidazoles 1(a-j) and 4-nitro-1-(hydroxyethyl)-1H-imidazole 2, an analog of metronidazole (MTZ), and assessed their trichomonacidal and cytotoxic effects. All compounds 1(a-j) and 2 exhibited IC50 values ≤ 20 μM and ≤ 41 μM, after 24 h and 48 h, respectively. Compounds 1d (IC50 5.3 μM), 1e (IC50 4.8 μM), and 1i (IC50 5.2 μM) exhibited potencies equivalent to MTZ (IC50 4.9 μM), the reference drug, after 24 h. Notably, compound 1i showed high anti-trichomonas activity after 24 h (IC50 5.2 μM) and 48 h (IC50 2.1 μM). Additionally, all compounds demonstrated either no...
Source: Bioorganic and Medicinal Chemistry - March 10, 2024 Category: Chemistry Authors: Rafaela Corr êa Silva Anna De Freitas Bruno Vicente Victor Midlej Maur ício Silva Dos Santos Source Type: research
Exploring novel pyrazole-nitroimidazole hybrids: Synthesis and antiprotozoal activity against the human pathogen trichomonas vaginalis
In this study, we synthesized ten pyrazole-nitroimidazoles 1(a-j) and 4-nitro-1-(hydroxyethyl)-1H-imidazole 2, an analog of metronidazole (MTZ), and assessed their trichomonacidal and cytotoxic effects. All compounds 1(a-j) and 2 exhibited IC50 values ≤ 20 μM and ≤ 41 μM, after 24 h and 48 h, respectively. Compounds 1d (IC50 5.3 μM), 1e (IC50 4.8 μM), and 1i (IC50 5.2 μM) exhibited potencies equivalent to MTZ (IC50 4.9 μM), the reference drug, after 24 h. Notably, compound 1i showed high anti-trichomonas activity after 24 h (IC50 5.2 μM) and 48 h (IC50 2.1 μM). Additionally, all compounds demonstrated either no...
Source: Bioorganic and Medicinal Chemistry - March 10, 2024 Category: Chemistry Authors: Rafaela Corr êa Silva Anna De Freitas Bruno Vicente Victor Midlej Maur ício Silva Dos Santos Source Type: research
Exploring novel pyrazole-nitroimidazole hybrids: Synthesis and antiprotozoal activity against the human pathogen trichomonas vaginalis
In this study, we synthesized ten pyrazole-nitroimidazoles 1(a-j) and 4-nitro-1-(hydroxyethyl)-1H-imidazole 2, an analog of metronidazole (MTZ), and assessed their trichomonacidal and cytotoxic effects. All compounds 1(a-j) and 2 exhibited IC50 values ≤ 20 μM and ≤ 41 μM, after 24 h and 48 h, respectively. Compounds 1d (IC50 5.3 μM), 1e (IC50 4.8 μM), and 1i (IC50 5.2 μM) exhibited potencies equivalent to MTZ (IC50 4.9 μM), the reference drug, after 24 h. Notably, compound 1i showed high anti-trichomonas activity after 24 h (IC50 5.2 μM) and 48 h (IC50 2.1 μM). Additionally, all compounds demonstrated either no...
Source: Bioorganic and Medicinal Chemistry - March 10, 2024 Category: Chemistry Authors: Rafaela Corr êa Silva Anna De Freitas Bruno Vicente Victor Midlej Maur ício Silva Dos Santos Source Type: research
